100mg vial of ghk cu Ghk-cu GHK-CU COPPER PEPTIDE 5MG/10MG/50MG/100MG VIAL

This result, again, verified that 1D228 target TRKB, c-Met, as well as AXL signaling

Hematocrit elevation above 54 percent indicates polycythemia risk (affecting up to 20 percent of TRT patients), requiring therapeutic phlebotomy or dose reduction

Australian Regulatory Guidelines for Prescription Medication

Pharmacokinetic Profile Route of Administration Subcutaneous Route of Administration : Subcutaneous Injection Formulation & Handling Supplied as a sterile, lyophilized powder Reconstitute with sterile water or buffer as per laboratory protocol Store lyophilized at -20C

Administration: Intramuscular (IM) or subcutaneous (SC) as directed by a healthcare provider